Free tool
FAERS Monitor: Arikayce Kit
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 207356 or its brand name (Arikayce Kit, Amikacin Sulfate). Reports on generic versions are filed under their own applications.
Reports
17,297
Serious
14,295
83% of reports
Hospitalization
7,341
Death reported
3,446
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use2,052
- drug ineffective1,836
- cough1,733
- dyspnoea1,666
- therapy interrupted1,437
- hospitalisation1,415
- death1,154
- dysphonia1,046
- nausea800
- product dose omission issue786
- fatigue781
- pneumonia703
- diarrhoea691
- pyrexia662
- condition aggravated654
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 137 |
| 2005 | 104 |
| 2006 | 98 |
| 2007 | 134 |
| 2008 | 136 |
| 2009 | 120 |
| 2010 | 146 |
| 2011 | 230 |
| 2012 | 212 |
| 2013 | 220 |
| 2014 | 209 |
| 2015 | 275 |
| 2016 | 408 |
| 2017 | 508 |
| 2018 | 811 |
| 2019 | 2,136 |
| 2020 | 1,812 |
| 2021 | 1,453 |
| 2022 | 1,387 |
| 2023 | 1,869 |
| 2024 | 2,088 |
| 2025 | 1,781 |
| 2026 | 1,023 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,036,862 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| therapy interruptedSignal | 1,437 | 24.9 | 23.7 | 32,433 |
| dysphoniaSignal | 1,046 | 22.1 | 20.8 | 20,756 |
| hospitalisationSignal | 1,415 | 11.3 | 10.7 | 13,239 |
| coughSignal | 1,733 | 7.6 | 7.2 | 9,921 |
| dyspnoeaSignal | 1,666 | 3.6 | 3.4 | 3,181 |
| product dose omission issueSignal | 786 | 3.3 | 3.0 | 1,241 |
| off label useSignal | 2,052 | 2.9 | 2.7 | 2,571 |
| pneumoniaSignal | 703 | 2.6 | 2.5 | 727 |
| condition aggravatedSignal | 654 | 2.6 | 2.4 | 661 |
| pyrexiaSignal | 662 | 2.3 | 2.2 | 508 |
| drug ineffective | 1,836 | 1.7 | 1.6 | 557 |
| death | 1,154 | 1.6 | 1.5 | 292 |
| diarrhoea | 691 | 1.3 | 1.2 | 50 |
| nausea | 800 | 1.2 | 1.1 | 35 |
| fatigue | 781 | 1.2 | 1.1 | 32 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.